Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease-Reference-Cited by-同舟云学术

Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease

Published:2018-09 Issue:3 Volume:29 Page:148-155
ISSN:2324-8637
Container-title:Human Gene Therapy Clinical Development
language:en
Short-container-title:Human Gene Therapy Clinical Development

Author:

Palfi Stéphane¹²,Gurruchaga Jean Marc¹²,Lepetit Hélène¹²,Howard Katy³,Ralph G. Scott³,Mason Sarah⁴,Gouello Gaëtane¹²,Domenech Philippe¹²,Buttery Philip C.⁴,Hantraye Philippe⁵,Tuckwell Nicola J.³,Barker Roger A.⁴,Mitrophanous Kyriacos A.³

Affiliation:

1. AP-HP, Groupe Hospitalier Henri-Mondor, DHU PePsy, Neurochirurgie, Psychiatrie Créteil, France.

2. Université Paris 12, Faculté de Médecine, IMRB INSERM U 955 Team 14 Créteil, France.

3. Oxford BioMedica Ltd., Oxford, United Kingdom.

4. John van Geest Centre for Brain Repair, Department of Clinical Neuroscience, Addenbrooke's Hospital, Cambridge, United Kingdom.

5. CEA, DSV FBM, MIRCen and CNRS URA2210, Fontenay-aux-Roses, France.

Publisher

Mary Ann Liebert Inc

Subject

Genetics(clinical)

Link

https://www.liebertpub.com/doi/pdf/10.1089/humc.2018.081